DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer

Pathobiology

Volumn 68, Issue 3, 2000, Pages 137-143

  Nakopoulou, Lydia ^a   Lazaris, Andreas C ^a   Kavantzas, Nikolaos ^a   Alexandrou, Paraskevi ^a   Athanassiadou, Pauline ^a   Keramopoulos, Antonios ^a   Davaris, Panayiotis ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

bcl 2; Breast cancer; c erbB 2; Immunohistochemistry; Ki 67; p53; Prognosis; Topoisomerase II

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) ALPHA; KI 67 ANTIGEN; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN C ERB2; PROTEIN P53; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER INVASION; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE ASSOCIATION; ENZYME ISOLATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL COUNT; CELL NUCLEUS; DISEASE-FREE SURVIVAL; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOENZYME TECHNIQUES; ISOENZYMES; KI-67 ANTIGEN; MENOPAUSE; MIDDLE AGED; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034486459     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055914     Document Type: Article

References (23)

1. Immunohistochemical staining of DNA topoisomerase IIα in human gliomas
2. Topoisomerase IIα expression in esophageal squamous cell carcinoma
3. Immunohistochemical and two-parameter flow cytometric studies of DNA topoisomerase II alpha in human epithelial ovarian carcinoma and germ cell tumor
4. Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: Correlation with DNA topoisomerase II-alpha and p53 expression
5. Immunohistochemical staining for DNA topoisomerase II in non-Hodgkin's lymphomas
6. Prognosis and breast cancer. Recognition of lethal and favorable prognostic types
7. Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis
8. Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer
9. Bcl-2 protein expression is associated with a prognostically favourable phenotype in breast cancer irrespective of p53 immunostaining
10. Histological grading of breast carcinomas: A study of interobserver agreement
11. Recommendations for the reporting of breast carcinoma
12. Staging and follow-up of breast cancer patients
13. Proliferating cell nuclear antigen and heat shock protein 70 immunolocalization in invasive ductal breast cancer not otherwise specified
14. Little missed markers and Ki-67
15. Human DNA topoisomerase II-alpha: A new marker of cell proliferation in invasive breast cancer
16. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer
17. Prognostic significance of Ki-67 and topoisomerase IIα expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases
18. Correlation between p53, c-erbB-2, and topoisomerase IIα expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: Prognostic implications
19. Topoisomerase IIalpha expression in breast cancer: Correlation with outcome variables
20. Pathobiologic characteristics of hereditary breast cancer
21. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer
22. Physiological regulation of eukaryotic topoisomerase II